Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia
- 19 May 2020
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (9), 2271-2273
- https://doi.org/10.1080/10428194.2020.1761965
Abstract
(2020). Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia. Leukemia & Lymphoma. Ahead of Print.This publication has 15 references indexed in Scilit:
- Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?Leukemia & Lymphoma, 2019
- Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issuesBlood Reviews, 2019
- Primary refractory B-cell lymphoblastic leukemia with extramedullary disease – a distinctive response to blinatumomab and inotuzumab ozogamicinHematology, Transfusion and Cell Therapy, 2019
- A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemiaHaematologica, 2019
- Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemiaBMC Cancer, 2018
- Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatmentCurrent Problems in Cancer, 2018
- Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR‐T containing either CD28 or 4‐1BBBritish Journal of Haematology, 2018
- A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemiaJournal of Hematology & Oncology, 2018
- Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemiaAmerican Journal of Hematology, 2017
- The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialHaematologica, 2013